Humacyte (HUMA) Projected to Post Earnings on Tuesday

Key Points

• Humacyte (HUMA) is expected to announce its Q2 2025 earnings on August 12th, with analysts projecting an earnings loss of ($0.15) per share and revenue of $0.94 million.
• The company's stock recently rose by 1.1%, closing at $2.29, and has a current market capitalization of $354.45 million.
• Analyst ratings are mixed, with one investment analyst giving a sell rating, while others have set price targets ranging from $4.00 to $25.00, reflecting varied outlooks on the stock's potential.

Humacyte (NASDAQ:HUMA - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $0.94 million for the quarter.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.09. The business had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.46 million. On average, analysts expect Humacyte to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Humacyte Stock Performance

NASDAQ HUMA traded up $0.18 during trading hours on Thursday, reaching $2.39. The company's stock had a trading volume of 927,941 shares, compared to its average volume of 3,733,187. The company has a current ratio of 3.68, a quick ratio of 3.28 and a debt-to-equity ratio of 0.36. The business has a 50-day simple moving average of $2.41 and a 200 day simple moving average of $2.59. Humacyte has a 52 week low of $1.15 and a 52 week high of $8.24. The stock has a market cap of $369.96 million, a PE ratio of -3.46 and a beta of 1.90.

Analyst Upgrades and Downgrades

HUMA has been the topic of a number of recent research reports. Wall Street Zen cut shares of Humacyte from a "hold" rating to a "sell" rating in a report on Friday, July 18th. Benchmark dropped their price target on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. HC Wainwright initiated coverage on shares of Humacyte in a research note on Wednesday, May 14th. They issued a "buy" rating and a $4.00 price target on the stock. Finally, D. Boral Capital restated a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research note on Wednesday, July 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $11.71.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.